Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Broxyquinoline SCHEMBL30485535 | 1.00 | KDM4E (1.00) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL29607319 | 1.00 | KDM4E (1.00) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL28536097 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL22734870 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL28909008 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL28500050 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL28528459 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL31157810 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL261708 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 | |
| Broxyquinoline SCHEMBL27633003 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | claimed |
| CN-118252950-A | Antibacterial nano material containing metal compound and preparation method and application thereof | 广东云曌医疗科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118178352-A | Antibacterial drug nano material and preparation method and application thereof | 广东云曌医疗科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118084897-A | Iron ion detection reagent and preparation method and application thereof | 河南省氟基新材料科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117402494-A | Complex high-strength polyarylene sulfide based composite material and preparation and application thereof | 新凝合科技(成都)有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116789683-A | 8-hydroxyquinoline anticancer zinc (II) complex and synthetic method and application thereof | 玉林师范学院 | 2023-09-22 | — | — | CN | claimed |
| CN-116789684-A | 8-hydroxyquinoline anticancer zinc (II) complex and synthetic method and application thereof | 玉林师范学院 | 2023-09-22 | — | — | CN | claimed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | claimed |
| US-20230103644-A1 | TREATMENT OF EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-06 | — | — | US | claimed |
| US-5001227-A | Fibre-reactive 1:1 chromium complex azo or azomethine dyes having a bidentate chelating group and a monofunctional neutral ligand | CIBA-GEIGY CORPORATION (US) | 1991-03-19 | — | — | US | claimed |
| EP-0144776-B1 | FIBRE-REACTIVE CHROMIUM COMPLEXES, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-10-11 | — | — | EP | claimed |
| EP-0145506-B1 | ELIMINATION OF DEFECTS IN CYSTEINE-SENSITIZED EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| US-4659683-A | DISSOLVING IN NITRIC ACID OR AQUA REGIA, NEUTRALIZATION OF THE SOLUTION, THEN PRECIPITATION OF IMPURITIES | BASF AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | claimed |
| EP-0096457-B1 | INDIUM COMPLEXES OF SUBSTITUTED 8-HYDROXY-QUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-03-11 | — | — | EP | claimed |
| EP-0145506-A2 | Elimination of defects in cysteine-sensitized emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-06-19 | — | — | EP | claimed |
| US-4520099-A | CONTAINING AN HYDROXYQUINOLINE AS AN ANTIFOGGING AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1985-05-28 | — | — | US | claimed |
| US-4514492-A | Elimination of defects in cysteine-sensitized emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | claimed |
| EP-0096457-A1 | Indium complexes of substituted 8-hydroxy-quinolines, pharmaceutical compositions containing them and their use as antibacterial agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-12-21 | — | — | EP | claimed |
| US-4025609-A | CHELATION | KAO SOAP CO., LTD. (JA) | 1977-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103644-A1 | TREATMENT OF EPILEPSY | SCN8A, KCNQ2, KCNQ5 | KDM4E 352/4885HSP90AA1 2749/4885MEN1 1485/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | KDM4E 2931/4885HSP90AA1 931/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.